TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18719048

Group type: EXPERIMENTAL
Intervention: 5-HTP/CBD/ granisetron
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5-HTP/CBD/domperidone
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5-HTP/CBD/placebo
Number of subjects: 12
Study: 18448569

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg (q.d.)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Quinidine 600 mg (b.i.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pactimibe sulfate without ketoconazole or quinidine
Number of subjects: 35
Study: 15989987

Group type: EXPERIMENTAL
Intervention: r‐FSH and LH (hMG 75 IU FSH + 75 IU LH activity daily for four days with r‐FSH 150 IU/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: r‐FSH (200 IU/day for the first four days)
Number of subjects: 46
Study: 12698090

Group type: EXPERIMENTAL
Intervention: pp67 mRNA NASBA
Number of subjects: 82

Group type: COMPARATOR
Intervention: Quantitative antigenemia
Number of subjects: 82
Study: 11002232

Group type: EXPERIMENTAL
Intervention: RT-CHOP (radiotherapy followed by six cycles of CHOP chemotherapy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: RT (radiotherapy alone)
Number of subjects: 53
Study: 8623886

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (200 mg and 400 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1729457

Group type: EXPERIMENTAL
Intervention: Oral vitamin A (60,000 micrograms retinol equivalent)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 6146341

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31593830

Group type: EXPERIMENTAL
Intervention: Matched molecularly targeted agents (MTAs) classified into ESCAT tiers II, IIIA, IIIB, and IVA
Number of subjects: 153
Study: 29855249

Group type: EXPERIMENTAL
Intervention: Growing rods surgery for severe EOS
Number of subjects: 107

Group type: COMPARATOR
Intervention: Growing rods surgery for moderate EOS
Number of subjects: 107
Study: 27735021

Group type: EXPERIMENTAL
Intervention: Alprostadil 60 mg and α-lipoic acid 600 mg in 250 mL normal saline, intravenous drip once per day for 2 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Tadalafil 5 mg orally, once per night for 2 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Alprostadil combined with α-lipoic acid
Number of subjects: 76

Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 76
Study: 24263619

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4 U/kg via subcutaneous injection once-daily for six days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 0
Study: 22908112

Group type: EXPERIMENTAL
Intervention: Parent/Adol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent Only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 20521272

Group type: EXPERIMENTAL
Intervention: GTFT 2.0 g/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GTFT 1.8 g/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GTFT 1.6 g/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GTFT 1.4 g/L
Number of subjects: 15
Study: 18478132

Group type: EXPERIMENTAL
Intervention: Capsule endoscopy (CE) in patients with PHT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Capsule endoscopy (CE) in controls (no PHT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Presence of PHE in patients with PHT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Presence of SB varices in patients with PHT
Number of subjects: 35
Study: 16186600

Group type: EXPERIMENTAL
Intervention: iodine‐131 tositumomab
Number of subjects: 250
Study: 12857652

Group type: EXPERIMENTAL
Intervention: Providing information about the severity of treatment and illness consequences
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Providing information about colorectal cancer risks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 119
Study: 10774083

Group type: EXPERIMENTAL
Intervention: Intermittent and continuous malaria chemoprophylaxis using chloroquine and proguanil
Number of subjects: 701

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 701
Study: 9001836

Group type: EXPERIMENTAL
Intervention: Mibefradil (6.25, 12.5, 25, 50, or 100 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 45
Study: 1291697

Group type: EXPERIMENTAL
Intervention: Group behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral marital treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 2951089

Group type: EXPERIMENTAL
Intervention: Human ultralente insulin (6 U)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bovine ultralente insulin (6 U)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Human ultralente insulin (24 U)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bovine ultralente insulin (24 U)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bovine ultralente insulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Human ultralente insulin
Number of subjects: 8
Study: 30726261

Group type: EXPERIMENTAL
Intervention: Risky substance use mentioned in C&P examination
Number of subjects: 208

Group type: COMPARATOR
Intervention: No risky substance use mentioned in C&P examination
Number of subjects: 208
Study: 30309276

Group type: EXPERIMENTAL
Intervention: Quarterly health coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monthly health coaching
Number of subjects: 0
Study: 26766172

Group type: EXPERIMENTAL
Intervention: Mailed assortment of HPDs with or without information
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Interactive web‐based information
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Static web‐based information
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Mailed assortment of HPDs
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Mailed and web‐based information groups
Number of subjects: 491

Group type: COMPARATOR
Intervention: Other interventions (static web-based information, interactive web-based information without mailed HPDs)
Number of subjects: 491
Study: 24933322

Group type: EXPERIMENTAL
Intervention: Focused attention condition (listening to audio instructions to pay attention to food)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control condition (listening to an audio book with neutral content)
Number of subjects: 48
Study: 22024949

Group type: EXPERIMENTAL
Intervention: 12-month physical activity (PA) intervention including aerobic, strength, and flexibility exercises, with walking as the primary mode.
Number of subjects: 361

Group type: COMPARATOR
Intervention: Successful aging intervention (control group).
Number of subjects: 361
Study: 20485203

Group type: EXPERIMENTAL
Intervention: BUD 400 microg twice daily for 1 month, then 200 microg twice daily for 5 months
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: BUD 100 microg twice daily
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: BUD as needed for 1 year
Number of subjects: 136

Group type: COMPARATOR
Intervention: DSCG
Number of subjects: 136
Study: 18377991

Group type: EXPERIMENTAL
Intervention: HFNY (Healthy Families New York)
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Control group (information and referrals to other services)
Number of subjects: 1173
Study: 15774210

Group type: EXPERIMENTAL
Intervention: PRFA
Number of subjects: 112

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 112
Study: 12404669

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study: 10369427

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg three times daily)
Number of subjects: 105
Study: 7590814

Group type: EXPERIMENTAL
Intervention: cA2 chimeric anti-TNF alpha antibody (1 mg/kg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: cA2 chimeric anti-TNF alpha antibody (10 mg/kg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (0.1% human serum albumin)
Number of subjects: 73
Study: 2351512

Group type: EXPERIMENTAL
Intervention: Enteric fever
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acute diarrhoeal diseases
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conjunctivitis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Scabies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Infective hepatitis
Number of subjects: 100
Study: 367480

Group type: EXPERIMENTAL
Intervention: Cyproheptadine with behaviour therapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cyproheptadine without behaviour therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo with behaviour therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo without behaviour therapy
Number of subjects: 81
Study: 30638416

Group type: EXPERIMENTAL
Intervention: Nivolumab/ipilimumab combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Markov model
Number of subjects: 0
Study: 28796276

Group type: EXPERIMENTAL
Intervention: Colistin (2.5 million IU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 26652335

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior-stabilized TKA
Number of subjects: 60
Study: 23146660

Group type: EXPERIMENTAL
Intervention: Infliximab (3mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21546160

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine infusion (100-hour continuous intravenous infusion at 10-20mg/h)
Number of subjects: 6
Study: 18505668

Group type: EXPERIMENTAL
Intervention: Oral NSAIDs
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Topical NSAIDs
Number of subjects: 585
Study: 16826054

Group type: EXPERIMENTAL
Intervention: Low-dose group (10 MU/0.1 mL saline)
Number of subjects: 23
Study: 12642540

Group type: EXPERIMENTAL
Intervention: Telephone assessment and triage using a computerized decision support system by nurses or paramedics.
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Control group (standard procedures without computerized decision support system)
Number of subjects: 1246
Study: 11101549

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone follow-up for incomplete questionnaires
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postal questionnaires
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional imputation of missing data
Number of subjects: 0
Study: 9067299

Group type: EXPERIMENTAL
Intervention: Nalbuphine 10 mg/70 kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nalbuphine 2.5 to 10 mg/70 kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Morphine 10 mg/70 kg
Number of subjects: 16
Study: 8090437

Group type: EXPERIMENTAL
Intervention: 38% water content lenses
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 67% water content lenses
Number of subjects: 26
Study: 2682012

Group type: EXPERIMENTAL
Intervention: Flow rate of 2.0 L.min‐1.m‐2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Flow rate of 1.5 L.min‐1.m‐2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonpulsatile or pulsatile perfusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attempted pH and alpha stat control
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Higher flow rate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lower flow rate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alteration in arterial pH
Number of subjects: 24

Group type: COMPARATOR
Intervention: Flow rate, flow character, or arterial pH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: During cardiopulmonary bypass
Number of subjects: 24
Study: 796856

Group type: EXPERIMENTAL
Intervention: Irradiation of crystalline substrates with an Hg vapor lamp
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-blind studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-blind studies
Number of subjects: 0
Study: 31281044

Group type: EXPERIMENTAL
Intervention: Current and ex-smokers
Number of subjects: 1987
Study: 30576842

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention to improve adherence to P2Y12 inhibitors
Number of subjects: 0
Study: 29097640

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPT‐SP) alone
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPT‐SP) and insecticide treated nets (ITN)
Number of subjects: 270

Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 270
Study: 25971920

Group type: EXPERIMENTAL
Intervention: Tooth extraction
Number of subjects: 179

Group type: COMPARATOR
Intervention: No extraction
Number of subjects: 179
Study: 24224515

Group type: EXPERIMENTAL
Intervention: Intranasal DEX 1 μg·kg(‐1) (group D1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intranasal DEX 2 μg·kg(‐1) (group D2)
Number of subjects: 40
Study: 22128226

Group type: EXPERIMENTAL
Intervention: Sildenafil (combined low-, medium-, high-dose)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Medium-dose sildenafil
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High-dose sildenafil
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low-dose sildenafil
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 19243716

Group type: EXPERIMENTAL
Intervention: High-dose varenicline (1 mg BID)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low-dose varenicline (0.5 mg BID)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low-dose varenicline (0.5 mg once daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (for high-body-weight group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (for low-body-weight group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High-dose varenicline (for low-body-weight group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low-dose varenicline (for low-body-weight group)
Number of subjects: 72
Study: 17559730

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% film-forming solution (FFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terbinafine 1% cream (Lamisil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Washing at 30 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Washing at 12 h
Number of subjects: 0
Study: 15008648

Group type: EXPERIMENTAL
Intervention: Context-dependent processing style induced in Experiment 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral mimicry by experimenter in Experiment 3
Number of subjects: 0
Study: 11800303

Group type: COMPARATOR
Intervention: Quinine sulfate 10 mg/kg/day for at least 7 days (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral artesunate 2 mg/kg as the first dose, 1 mg/kg every 12 hours orally for at least 5 days together with split doses of mefloquine, 15 mg/kg and 6 hours later 10 mg/kg orally 1 day after artesunate was stopped (group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study: 9192123

Group type: EXPERIMENTAL
Intervention: Atenolol (25-100 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 42
Study: 1327634

Group type: EXPERIMENTAL
Intervention: L-alanine infusion (0.70, 1.40, or 2.80 nmol/kg body weight over 4.5 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: L-alanine infusion (11.2 mmol/kg body weight in male Wistar rats)
Number of subjects: 6
Study: 2947712

Group type: EXPERIMENTAL
Intervention: Yukuiling
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Weidening
Number of subjects: 250
Study: 31293098

Group type: EXPERIMENTAL
Intervention: 1 × 10 min of Finnish sauna bathing (80.2 ± 3.2°C, 23 ± 2% humidity)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 × 10 min of sauna bathing separated by 10 min of rest outside the sauna
Number of subjects: 21

Group type: COMPARATOR
Intervention: Time control period (10 min of seated rest outside the sauna)
Number of subjects: 21
Study: 29633373

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks thereafter until Week 52
Number of subjects: 160

Group type: COMPARATOR
Intervention: Narrow-band ultraviolet B (nb-UVB) phototherapy, one/two cycles for 12 weeks each (maximum 28-week break between cycles)
Number of subjects: 160
Study: 26549475

Group type: EXPERIMENTAL
Intervention: High increasing trajectory group (11.6%)
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Very high trajectory group (1.9%)
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Consistently low trajectory group (51.1%)
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Consistently moderate trajectory group (29.8%)
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: High declining trajectory group (5.5%)
Number of subjects: 1216
Study: 24449005

Group type: EXPERIMENTAL
Intervention: Spatially congruent sound condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spatially incongruent sound condition
Number of subjects: 0
Study: 23095370

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Continuous venovenous hemodialysis (CVVHD)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 78

Group type: COMPARATOR
Intervention: CVVHD
Number of subjects: 78
Study: 19910621

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 2463

Group type: EXPERIMENTAL
Intervention: BIS values <40 for >5 min
Number of subjects: 2463
Study: 17638700

Group type: EXPERIMENTAL
Intervention: Doxycycline (7-day course)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Azithromycin (3-day course)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Doxycycline and Azithromycin
Number of subjects: 296
Study: 16164829

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (AT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 11918500

Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids
Number of subjects: 53

Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 53
Study: 9805221

Group type: EXPERIMENTAL
Intervention: Electronic visual analogue scale (Apple Newton Message Pad)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Paper visual analogue scale questionnaire
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preference assessment after both methods
Number of subjects: 12
Study: 7631609

Group type: EXPERIMENTAL
Intervention: Warfarin (n = 32)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Warfarin and Placebo
Number of subjects: 55
Study: 2280168

Group type: EXPERIMENTAL
Intervention: Irlen filter treatment group (n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vision therapy treatment group (n = 11)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 30
Study: 6107987

Group type: EXPERIMENTAL
Intervention: Somatostatin (600 pg/ml) added to distending fluid during 3 test periods in 10 subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo added to distending fluid during 3 test periods in 10 control subjects
Number of subjects: 20
Study: 31008641

Group type: EXPERIMENTAL
Intervention: Expectancy Challenge Alcohol Literacy Curriculum (ECALC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 121
Study: 31464617

Group type: EXPERIMENTAL
Intervention: Wuzi Yanzong pill
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28859942

Group type: EXPERIMENTAL
Intervention: Quality improvement educational intervention
Number of subjects: 2281

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2281
Study: 26449227

Group type: EXPERIMENTAL
Intervention: Diazepam (final dose 0.07 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl (final dose 1.11 μg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine (final dose 0.084 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 0
Study: 23584193

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 772
Study: 21540865

Group type: EXPERIMENTAL
Intervention: Cilengitide (500, 1000 and 2000 mg) combined with cetuximab, cisplatin and 5-fluorouracil
Number of subjects: 10
Study: 19718255

Group type: EXPERIMENTAL
Intervention: Naturopathic care (NC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standardized psychotherapy intervention (PT)
Number of subjects: 81
Study: 17875819

Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15468362

Group type: EXPERIMENTAL
Intervention: Doxycycline + Rifampin (D/R)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Doxycycline (D)
Number of subjects: 30
Study: 11583883

Group type: EXPERIMENTAL
Intervention: Clinical and six-month angiographic follow-up
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Clinical follow-up alone
Number of subjects: 1058
Study: 11301566

Group type: EXPERIMENTAL
Intervention: Intramuscular progestin therapy (medroxyprogesterone acetate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral progestin therapy (medroxyprogesterone acetate)
Number of subjects: 12
Study: 8165049

Group type: EXPERIMENTAL
Intervention: Fluoride supplement (0.013 mmol or 0.25 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (control study)
Number of subjects: 17